Prognostic Impact Of Type Ⅰ Collagen Alpha 1 Chain And E-Cadherin In Triple Negative Breast Cancer

Objective: To investigate the effects of type I collagen α1 chain(COL1A1)and E-cadherin(E-C)on the hyperplasia,invasion and relocation of TNBC cells,and to explore their relationship with the clinicopathological characteristics of TNBC and patient prognosis.Methods: The expression status of COL1A1 was detected by immunohistochemistry,a COL1A1 low expression breast cancer cell line was constructed by lentiviral transfection,exosomes were extracted by exo Rasy Maxi kit,and the exosomes were co-cultured with fibroblasts,and the gene expression of E-cadherin was tested by PCR,and the protein expression of E-cadherin was detected by Western blot,and analyze the relationship between COL1A1 expression status and E-cadherin expression,so as to explore the process of COL1A1 mediating TME through E-C and the role in triple negative breast cancer.Results: RT-p CR assay showed that the expression level of co-cultured E-cadherin gene expression in exosomes and fibroblasts was significantly down-regulated compared to the negative control group(p < 0.05),and the E-cadherin mRNA expression levels in the negative control and experimental groups were0.580 ± 0.124 and 0.958 ± 0.213,respectively,compared to the negative control group Western blot assay showed that the expression levels of E-cadherin protein in HKF cells and blank control group were 0.804±0.051 and 0.420±0.046,respectively,and compared with normal fibroblasts,the expression levels of E-cadherin protein in blank control group were significantly downregulated(p<0.05;Figure 2).E-cadherin protein expression was significantly downregulated in the blank control group compared to normal fibroblasts(p< 0.05),and the E-cadherin protein expression levels were 0.500 ± 0.080 and 0.676 ±0.037 in the negative control and experimental groups,respectively,compared to the negative control group(p<0.05)Conclusion:The combination of COL1A1 overexpression and reduced E-cadherin expression may be a better predictor of prognosis in triple-negative breast cancer than a single marker.